Celldex Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Celldex Therapeutics, Inc. (CLDX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-157.86-141.43-112.33-70.51-59.78-50.88-151.18
Depreciation & Amortization3.183.012.903.073.933.723.80
Deferred Income Tax0.000.000.00-0.23-1.170.00-0.77
Stock Based Compensation34.2423.8915.618.953.920.000.00
Change in Working Capital-21.6013.46-3.90-1.05-0.30-4.32-15.37
Change in Accounts Receivable1.93-2.28-0.181.57-0.790.000.00
Change in Accounts Payable0.009.383.123.651.640.000.00
Change in Other Working Capital-23.536.36-6.86-1.41-1.150.000.00
Other Operating Activities-15.7317.67-6.86-1.41-5.396.35-29.62
Net Cash from Operating Activities-157.78-107.29-103.73-60.91-40.40-46.42-75.24
Investing Activities
Capital Expenditures-1.92-1.82-1.83-1.25-1.550.73-0.81
Acquisitions0.000.00-6.90-1.41-4.22-1.290.00
Purchases of Investments-789.92-424.56-188.97-389.88-96.720.000.00
Sales/Maturities of Investments501.71320.60280.67174.95-96.7217.7930.29
Other Investing Activities0.000.000.000.000.000.000.34
Net Cash from Investing Activities-290.13-105.7889.94-216.16-98.2217.0829.82
Financing Activities
Debt Repayment0.000.000.000.00-2.960.000.00
Common Stock Issued432.30216.224.08269.89171.2316.2629.02
Other Financing Activities9.150.000.000.000.000.000.00
Net Cash from Financing Activities441.45218.464.08272.37171.2316.2629.44
Summary
Net Change in Cash-6.465.39-9.71-4.6932.60-13.08-15.98
Cash at Beginning of Period34.8129.4339.1443.8411.2324.3140.29
Cash at End of Period28.36213.3129.4339.1443.8424.3124.31
Free Cash Flow-159.70-107.29-105.56-62.16-41.96-47.13-76.05